EXCLUSIVE: BioNTech 2019 SEC Filing to Investors Shows Company Doubted mRNA Technology Would Ever Get Approved

EXCLUSIVE: BioNTech 2019 SEC Filing to Investors Shows Company Doubted mRNA Technology Would Ever Get Approved


BioNTech is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.

The company formed a partnership with Pfizer in 2020 to develop an experimental COVID-19 mRNA injection.

Pfizer explains their partnership:

Trending: WATCH: Republican Voter In Florida Congressional Race Was Told By Poll Worker That Republicans Could Not Vote

Pfizer and BioNTech to jointly develop COVID-19 vaccine, initially in the United States and Europe, and scale-up manufacturing capacity to support global supply Potential to supply millions of vaccine doses by the end of 2020 subject to technical success of the development program and approval by regulatory authorities, and then rapidly scale up capacity to produce hundreds of millions of doses in 2021. BioNTech will contribute multiple mRNA vaccine candidates as part of its BNT162 COVID-19 vaccine program, which are

Continue reading

You Might Like

 

Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Thanks for sharing!
Send this to a friend